Camlin Fine Sciences reported a consolidated net loss of ₹336.22 million for the quarter ended June 30, 2026, widening significantly from a net loss of ₹106.81 million in the corresponding quarter of the previous year. The deterioration in profitability was primarily driven by significant foreign exchange losses of ₹83.69 million and an exceptional item of ₹108.80 million related to an insurance claim shortfall, which offset a robust 27.50% year-on-year growth in consolidated revenue from operations to ₹5,198.79 million.

The Board of Directors approved the unaudited financial results at a meeting held on August 11, 2026, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Kalyaniwalla & Mistry LLP. The company also disclosed that it has restructured its segment reporting to reflect three distinct business units: Specialty Ingredients, Aroma, and Performance Chemicals & Others.

Consolidated revenue from operations surged to ₹5,198.79 million from ₹4,077.21 million in Q1FY26. Standalone revenue also grew 16.20% to ₹2,224.86 million from ₹1,914.38 million in the prior year period. However, total expenses increased disproportionately. Standalone total expenses rose to ₹2,425.60 million from ₹2,115.04 million, while consolidated expenses climbed to ₹5,437.65 million from ₹4,184.18 million. This cost inflation resulted in a pre-tax loss from continuing operations of ₹322.59 million on a consolidated basis, compared to a loss of ₹31.79 million in the same quarter last year.

Key Financial Metrics

The following table summarises the standalone and consolidated financial performance for the quarter:

Segment Performance

The Specialty Ingredients segment remained the primary revenue driver, contributing ₹4,013.17 million to gross segment revenue, up from ₹2,936.08 million in Q1FY26. The Aroma segment saw robust growth, with revenue jumping to ₹774.07 million from ₹566.88 million. Performance Chemicals & Others contributed ₹1,748.90 million. While Specialty Ingredients generated a positive segment result of ₹254.66 million, the Aroma segment incurred a loss of ₹33.81 million, and Performance Chemicals & Others posted a loss of ₹44.41 million.

Management highlighted that the Aroma segment's loss was due to low capacity utilization during the cautious ramp-up of ethyl vanillin production. Approximately 350 metric tons of ethyl vanillin and 200 metric tons of methyl vanillin were sold. With a total capacity of 6,000 tons and an achievable rate of 5,000 tons, the company estimates annual production of around 3,000 tons for FY27, representing 60-70% utilization. Management expects the Aroma segment to turn positive in Q2FY27 as capacity utilization improves and the mix shifts back to higher-margin methyl vanillin.

Working Capital and Debt

Gross debt stood at ₹6,400 million as on June 30, 2026, down from ₹6,700 million as on March 31, 2026, primarily due to prepayments on long-term loans from IFC and EXIM Bank for the vanillin plant. However, management indicated that working capital requirements are elongating due to geopolitical disruptions affecting shipping routes (Hormuz Strait and Red Sea issues) and slower customer recoveries. The company may need to raise additional credit lines of ₹1,000 million to ₹2,000 million during the year to support working capital needs for projected revenue growth.

What the Numbers Show

The widening consolidated loss and sharp EBITDA contraction are largely attributable to non-operational factors rather than core operational inefficiencies. The company recorded a foreign exchange loss of ₹83.69 million under finance costs, significantly impacting the bottom line. Additionally, an exceptional item of ₹108.80 million was recognised due to a shortfall in the settlement of an insurance claim regarding a fire incident at CFS Do Brasil Industria in February 2026. These one-off charges masked the underlying revenue growth, indicating that the operational engine is expanding even as external financial headwinds compress net margins.

Other Developments

The company completed the acquisition of minority stakes in Vinpai S.A., increasing its holding to 95.41% following an open offer that closed on July 6, 2026. The transaction involved the transfer of 501,842 equity shares for ₹194.63 million. Furthermore, management confirmed that the loss from machinery and inventory due to a fire at the Diphenol manufacturing unit in Dahej on May 23, 2026, amounting to ₹67.03 million, is fully covered by insurance claims, with no residual loss expected. The liquidation process of CFS Europe SpA continues, with legal expenses of ₹2.50 million booked under discontinued operations.

Camlin Fine Sciences Limited shareholders approved the company’s audited financial statements for FY26 and reappointed two non-executive directors at its 33rd Annual General Meeting (AGM) held on August 11, 2026. The meeting, chaired by Chairman and Managing Director Ashish Dandekar, was conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI) circulars. All four resolutions passed with requisite majority, reflecting strong stakeholder alignment.

The AGM transacted ordinary business including the adoption of standalone and consolidated financial statements for FY26, alongside the re-appointment of Harsha Raghavan and Jens Van Nieuwenborgh as Non-Executive Non-Independent Directors, who retired by rotation. Under special business, shareholders ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The proceedings were scrutinized by Jayant Ranade of JHR & Associates, appointed as Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI Listing Regulations.

Voting participation was robust, with 56.83% of outstanding shares polled across all resolutions. Promoter and Promoter Group shareholders, holding 92,264,053 shares, voted in favor of all resolutions with 100% support. Public Institutional shareholders also demonstrated high engagement, polling over 84% of their holdings. Remote e-voting was open from August 8 to August 10, 2026, while additional voting occurred during the live meeting session.

Voting Results Summary

The Statutory Auditor’s report contained no qualifications or adverse remarks, as noted by the Chairman during the proceedings. The Scrutinizer’s consolidated report confirmed that no invalid votes were identified during the scrutiny process. A limited number of abstentions were recorded for specific resolutions but were classified separately as votes not cast.

What the Numbers Show

The near-unanimous approval of all resolutions underscores stable shareholder confidence in Camlin Fine Sciences’ governance structure. The promoter group’s complete alignment with all proposals, combined with high institutional participation, suggests minimal dissent regarding the company’s strategic direction and financial reporting for FY26. The negligible percentage of votes against any resolution indicates broad consensus among equity holders.